Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Recommendation of “Buy” from Analysts

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) have earned a consensus rating of “Buy” from the eight brokerages that are covering the stock, Marketbeat reports. Six investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $25.67.

Several brokerages have commented on ATXS. HC Wainwright reiterated a “buy” rating and issued a $16.00 target price on shares of Astria Therapeutics in a report on Thursday, February 27th. Oppenheimer raised their price target on shares of Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a report on Thursday, November 14th. Citizens Jmp upgraded shares of Astria Therapeutics to a “strong-buy” rating in a report on Friday, January 31st. Finally, JMP Securities assumed coverage on shares of Astria Therapeutics in a report on Friday, January 31st. They set an “outperform” rating and a $26.00 price target for the company.

Astria Therapeutics Price Performance

Shares of ATXS opened at $6.10 on Tuesday. Astria Therapeutics has a one year low of $6.07 and a one year high of $16.90. The company has a 50-day moving average of $7.63 and a two-hundred day moving average of $9.85. The stock has a market cap of $344.25 million, a price-to-earnings ratio of -2.92 and a beta of 0.67.

Hedge Funds Weigh In On Astria Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. FMR LLC raised its position in Astria Therapeutics by 29.2% during the third quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock valued at $86,123,000 after acquiring an additional 1,767,714 shares in the last quarter. RA Capital Management L.P. raised its position in Astria Therapeutics by 1.2% during the third quarter. RA Capital Management L.P. now owns 5,105,213 shares of the biotechnology company’s stock valued at $56,208,000 after acquiring an additional 61,457 shares in the last quarter. Vestal Point Capital LP raised its position in Astria Therapeutics by 4.5% during the fourth quarter. Vestal Point Capital LP now owns 4,180,000 shares of the biotechnology company’s stock valued at $37,369,000 after acquiring an additional 180,000 shares in the last quarter. Fcpm Iii Services B.V. bought a new position in Astria Therapeutics during the fourth quarter valued at approximately $25,680,000. Finally, Vanguard Group Inc. raised its position in Astria Therapeutics by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 2,677,353 shares of the biotechnology company’s stock valued at $23,936,000 after acquiring an additional 41,833 shares in the last quarter. Institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.